MSTN and neoplasm: Our findings demonstrated that circulating Mstn levels are comparable across these groups (Supplementary Fig. 1A), suggesting that the presence of primary tumor cells, either alone or accompanied by bone metastases, does not significantly impact systemic Mstn concentrations relative to non-metastatic controls.